A Nomogram Based on the Castelli Risk Index for Predicting Prognosis in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Cohort Study.

Publisher: John Wiley and Sons Ltd Country of Publication: England NLM ID: 101635460 Publication Model: Print Cited Medium: Internet ISSN: 2050-4527 (Electronic) Linking ISSN: 20504527 NLM ISO Abbreviation: Immun Inflamm Dis Subsets: MEDLINE

Original Publication: [Oxford] : John Wiley and Sons Ltd, [2013]-

Acute Coronary Syndrome*/surgery ; Acute Coronary Syndrome*/mortality ; Acute Coronary Syndrome*/diagnosis ; Acute Coronary Syndrome*/blood ; Percutaneous Coronary Intervention* ; Nomograms*; Humans ; Female ; Male ; Prognosis ; Middle Aged ; Aged ; Prospective Studies ; Risk Assessment ; Risk Factors ; Cohort Studies

Background and Aims: Composite lipid indices are closely related to the risk and poor prognosis of diseases. However, there are no studies on the prognostic value of Castelli's risk indices-I and II (CRI-I, CRI-II) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Therefore, the aim of this study was to investigate the association of CRI-I and CRI-II with the prognosis of patients with ACS undergoing PCI.
Patients and Methods: A total of 1475 patients with ACS undergoing PCI were consecutively enrolled in this prospective cohort study from January 2016 to December 2018. The CRI-I and CRI-II were measured. The endpoints were MACEs, including all-cause mortality, requirement of rehospitalization for severe heart failure, recurrence of myocardial infarction, in-stent restenosis, and reaccept PCI. Follow-up data were collected via clinical visits or telephone calls at 1, 3, 6, and 12 months and annually thereafter.
Result: Multivariable Cox regression analysis revealed that the risk of MACEs increased gradually with increasing CRI-I and CRI-II. The cumulative survival rate in the CRI-I ≥ 3.350 and CRI-II ≥ 1.697 groups was significantly lower than that in the CRI-I < 3.350 and CRI-II < 1.697 groups, respectively (log-rank tests: all p < 0.001). The nomogram demonstrated good predictive performance for the 1-, 2-, and 3-year survival probability.
Conclusions: CRI-I ≥ 3.350 and CRI-II ≥ 1.697 could serve as independent predictors of MACEs in patients with ACS undergoing PCI.
(© 2026 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.)

B. A. Bergmark, N. Mathenge, P. A. Merlini, M. B. Lawrence‐Wright, and R. P. Giugliano, “Acute Coronary Syndromes,” Lancet 399, no. 10332 (2022): 1347–1358, https://doi.org/10.1016/S0140-6736(21)02391-6.
D. L. Bhatt, R. D. Lopes, and R. A. Harrington, “Diagnosis and Treatment of Acute Coronary Syndromes: A Review,” Journal of the American Medical Association 327, no. 7 (2022): 662, https://doi.org/10.1001/jama.2022.0358.
T. M. Waterbury, G. Tarantini, B. Vogel, R. Mehran, B. J. Gersh, and R. Gulati, “Non‐Atherosclerotic Causes of Acute Coronary Syndromes,” Nature Reviews Cardiology 17, no. 4 (2020): 229–241, https://doi.org/10.1038/s41569-019-0273-3.
A. Pirillo, M. Casula, E. Olmastroni, G. D. Norata, and A. L. Catapano, “Global Epidemiology of Dyslipidaemias,” Nature Reviews Cardiology 18, no. 10 (2021): 689–700, https://doi.org/10.1038/s41569-021-00541-4.
G. K. Jakubiak, G. Cieślar, and A. Stanek, “Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients With Type 2 Diabetes: What do we Know and What Remains to be Explained?,” Antioxidants 11, no. 5 (2022): 856, https://doi.org/10.3390/antiox11050856.
J. Robertson, M. J. Peters, I. B. McInnes, and N. Sattar, “Changes in Lipid Levels With Inflammation and Therapy in RA: A Maturing Paradigm,” Nature Reviews Rheumatology 9, no. 9 (2013): 513–523, https://doi.org/10.1038/nrrheum.2013.91.
R. Peng and Y. Li, “Low Serum Thyroid‐Stimulating Hormone Levels are Associated With Lipid Profile in Depressive Patients With Long Symptom Duration,” Journal of Affective Disorders 217 (2017): 99–104, https://doi.org/10.1016/j.jad.2017.03.055.
M. Mahdavi‐Roshan, M. Mozafarihashjin, N. Shoaibinobarian, et al., “Evaluating the Use of Novel Atherogenicity Indices and Insulin Resistance Surrogate Markers in Predicting the Risk of Coronary Artery Disease: A Case–Control Investigation With Comparison to Traditional Biomarkers,” Lipids in Health and Disease 21, no. 1 (2022): 126, https://doi.org/10.1186/s12944-022-01732-9.
Y. Li, Y. Feng, S. Li, et al., “The Atherogenic Index of Plasma (AIP) is a Predictor for the Severity of Coronary Artery Disease,” Frontiers in Cardiovascular Medicine 10 (2023): 1140215, https://doi.org/10.3389/fcvm.2023.1140215.
A. Afsin, H. Kaya, A. Suner, et al., “Plasma Atherogenic Indices are Independent Predictors of Slow Coronary Flow,” BMC Cardiovascular Disorders 21, no. 1 (2021): 608, https://doi.org/10.1186/s12872-021-02432-5.
J. Guo, A. Wang, Y. Wang, et al., “Non‐Traditional Lipid Parameters as Potential Predictors of Asymptomatic Intracranial Arterial Stenosis,” Frontiers in Neurology 12 (2021): 679415, https://doi.org/10.3389/fneur.2021.679415.
Z. Zhao, H. Wang, Q. Hou, Y. Zhou, and Y. Zhang, “Non‐Traditional Lipid Parameters as Potential Predictors of Carotid Plaque Vulnerability and Stenosis in Patients With Acute Ischemic Stroke,” Neurological Sciences 44, no. 3 (2023): 835–843, https://doi.org/10.1007/s10072-022-06472-3.
S. Yu, L. Yan, J. Yan, et al., “The Predictive Value of Nontraditional Lipid Parameters for Intracranial and Extracranial Atherosclerotic Stenosis: A Hospital‐Based Observational Study in China,” Lipids in Health and Disease 22, no. 1 (2023): 16, https://doi.org/10.1186/s12944-022-01761-4.
W. Fan, C. Wei, Y. Liu, et al., “The Prognostic Value of Hematologic Inflammatory Markers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention,” Clinical and Applied Thrombosis/Hemostasis 28 (2022): 107602962211461, https://doi.org/10.1177/10760296221146183.
X. Wang, C. Wei, W. Fan, et al., “Advanced Lung Cancer Inflammation Index for Predicting Prognostic Risk for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention,” Journal of Inflammation Research 16 (2023): 3631–3641, https://doi.org/10.2147/JIR.S421021.
W. Fan, Y. Zhang, X. Gao, et al., “The Prognostic Value of a Derived Neutrophil‐Lymphocyte Ratio in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention,” Clinical and Applied Thrombosis/Hemostasis 27 (2021): 107602962110345, https://doi.org/10.1177/10760296211034579.
I. F. Charo and R. Taub, “Anti‐Inflammatory Therapeutics for the Treatment of Atherosclerosis,” Nature Reviews Drug Discovery 10, no. 5 (2011): 365–376, https://doi.org/10.1038/nrd3444.
P. B. Duell, F. K. Welty, M. Miller, et al., “Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association,” Arteriosclerosis, Thrombosis, and Vascular Biology 42, no. 6 (2022): 168–185, https://doi.org/10.1161/ATV.0000000000000153.
A. Javadifar, S. Rastgoo, M. Banach, T. Jamialahmadi, T. P. Johnston, and A. Sahebkar, “Foam Cells as Therapeutic Targets in Atherosclerosis With a Focus on the Regulatory Roles of Non‐Coding RNAs,” International Journal of Molecular Sciences 22, no. 5 (2021): 2529, https://doi.org/10.3390/ijms22052529.
A. Gisterå and G. K. Hansson, “The Immunology of Atherosclerosis,” Nature Reviews Nephrology 13, no. 6 (2017): 368–380, https://doi.org/10.1038/nrneph.2017.51.
M. Macvanin, Z. Gluvic, A. Klisic, et al., “The Link Between miRNAs and PCKS9 in Atherosclerosis,” Current Medicinal Chemistry 31: 1–31, https://doi.org/10.2174/0109298673262124231102042914.
Q. Hou, S. Li, Y. Gao, and H. Tian, “Relations of Lipid Parameters, Other Variables With Carotid Intima‐Media Thickness and Plaque in the General Chinese Adults: An Observational Study,” Lipids in Health and Disease 17, no. 1 (2018): 107, https://doi.org/10.1186/s12944-018-0758-9.
S. J. Pocock, A. G. Shaper, and A. N. Phillips, “Concentrations of High Density Lipoprotein Cholesterol, Triglycerides, and Total Cholesterol in Ischaemic Heart Disease,” BMJ 298, no. 6679 (1989): 998–1002, https://doi.org/10.1136/bmj.298.6679.998.
H. J. Pownall, C. Rosales, B. K. Gillard, and A. M. Gotto, “High‐Density Lipoproteins, Reverse Cholesterol Transport and Atherogenesis,” Nature Reviews Cardiology 18, no. 10 (2021): 712–723, https://doi.org/10.1038/s41569-021-00538-z.
M. Walter, “Interrelationships Among HDL Metabolism, Aging, and Atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology 29, no. 9 (2009): 1244–1250, https://doi.org/10.1161/ATVBAHA.108.181438.
C. Liu, D. Dhindsa, Z. Almuwaqqat, et al., “Association Between High‐Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High‐Risk Populations,” JAMA Cardiology 7, no. 7 (2022): 672–680, https://doi.org/10.1001/jamacardio.2022.0912.
P. Linsel‐Nitschke and A. R. Tall, “HDL as a Target in the Treatment of Atherosclerotic Cardiovascular Disease,” Nature Reviews Drug Discovery 4, no. 3 (2005): 193–205, https://doi.org/10.1038/nrd1658.
D. G. Karalis, “Intensive Lowering of Low‐Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease,” Mayo Clinic Proceedings 84, no. 4 (2009): 345–352, https://doi.org/10.1016/S0025-6196(11)60544-2.
E. A. Stein and F. J. Raal, “Targeting LDL: Is Lower Better and is it Safe?,” Best Practice & Research Clinical Endocrinology & Metabolism 28, no. 3 (2014): 309–324, https://doi.org/10.1016/j.beem.2013.10.010.
O. Acar, G. A. Sarac, D. D. Rota, and H. Aksoy, “Evaluation of Pro‐Atherogenic Lipid Profile and High Atherohenic Indexes in Patients With Behçet's Disease: A Case–Control Study,” Journal of Cosmetic Dermatology 22, no. 6 (2023): 1887–1892, https://doi.org/10.1111/jocd.15647.
L. S. Albuquerque, N. R. T. Damasceno, F. N. Maia, et al., “Cardiovascular Risk Estimated in Individuals With Multiple Sclerosis: A Case‐Control Study,” Multiple Sclerosis and Related Disorders 54 (2021): 103133, https://doi.org/10.1016/j.msard.2021.103133.
Y. T. Tien, L. J. Wang, Y. Lee, et al., “Comparative Predictive Efficacy of Atherogenic Indices on Metabolic Syndrome in Patients With Schizophrenia,” Schizophrenia Research 262 (2023): 95–101, https://doi.org/10.1016/j.schres.2023.10.023.
A. Klisic, N. Kavaric, A. Ninic, and J. Kotur‐Stevuljevic, “Oxidative Stress and Cardiometabolic Biomarkers in Patients With Non‐Alcoholic Fatty Liver Disease,” Scientific Reports 11, no. 1 (2021): 18455, https://doi.org/10.1038/s41598-021-97686-6.
S. Gunay‐Polatkan, S. Caliskan, and D. Sigirli, “Association of Atherogenic Indices With Myocardial Damage and Mortality in COVID‐19,” PLoS One 19, no. 5 (2024): e0302984, https://doi.org/10.1371/journal.pone.0302984.

CXZZSS2025116 Hebei Provincial Department of Education Graduate Innovation Funding Project

Keywords: composite lipid indices; dyslipidemia, high‐density lipoprotein cholesterol; low‐density lipoprotein cholesterol; major adverse cardiovascular events

Date Created: 20260408 Date Completed: 20260408 Latest Revision: 20260410

20260410

PMC13058236

10.1002/iid3.70431

41947487